drugset / Trial / NCT06441084
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
Phase 1
Not yet recruiting
15 enrolled
Nuwacell Biotechnologies Co., Ltd.
Beijing Friendship Hospital · collab
NaSingle-groupOpen-labelPrevention
Summary
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
Timeline
- Start
- 2024-06-30
- Primary completion
- 2028-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NCR300 | Unknown | — | — |